[144] Idaho Strategic Resources, Inc. SEC Filing

Rhea-AI Filing Summary

Form 4 filing overview

On July 8, 2025 Agios Pharmaceuticals, Inc. (AGIO) granted Director Jay T. Backstrom two equity awards:

• 23,393 non-qualified stock options at an exercise price of $36.28, vesting 25 % after one year and monthly thereafter through July 2029; expiration July 8, 2035.
• 4,341 restricted stock units (RSUs) convertible into one share each, vesting in three equal annual tranches starting July 8, 2026.

After the grant, Backstrom beneficially owns 23,393 options and 4,341 RSUs, all held directly.

The transaction is coded “A,” indicating a company-issued award rather than an open-market purchase, and no shares were sold. No financial performance metrics or strategic disclosures are included, making this a routine compensation event that modestly aligns the director’s incentives with shareholder interests.

Insights

Corporate Governance Analyst

TL;DR: Routine director equity grant; neutral market impact.

This Form 4 records standard board compensation—23,393 options at $36.28 and 4,341 RSUs to Director Jay Backstrom. Vesting terms (four-year for options, three-year for RSUs) promote long-term alignment but do not materially alter ownership structure or signal management sentiment. No cash sales occurred, so dilution is limited to future option exercises. Investors typically view such grants as ordinary course and not indicative of short-term performance trends.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	100000	1527070.00	14056438	07/10/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/06/2022	Private Acquisition from Issuer/Affiliate	Issuer			35088	02/06/2022	Cash
Common	08/30/2013	Private Acquisition from Issuer/Affiliate	Issuer			64912	08/30/2013	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What insider transaction did AGIO report on Form 4 dated July 10, 2025?

Director Jay T. Backstrom was granted 23,393 stock options at $36.28 and 4,341 RSUs on July 8, 2025.

What are the vesting terms of Jay Backstrom’s AGIO stock options?

The options vest 25 % on July 8, 2026 with the remaining 75 % vesting in 36 equal monthly installments thereafter and expire July 8, 2035.

When do the restricted stock units granted to Jay Backstrom vest?

The 4,341 RSUs begin vesting on July 8, 2026 in three equal annual installments.

Did the Form 4 filing disclose any share sales by the director?

No. The filing codes the transaction as "A" (acquisition) and shows no dispositions or sales.

How many derivative securities does Jay Backstrom own after the transaction?

Following the grant, he directly holds 23,393 stock options and 4,341 RSUs.